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ORIGINAL ARTICLE
Clinical features of children and adults with a muscular dystrophy using powered
indoor/outdoor wheelchairs: disease features, comorbidities and complications
of disability
Andrew Oliver Franka,b and Lorraine H. De Souzab
aStanmore Specialist Wheelchair Service, Royal National Orthopaedic Hospital Stanmore, Middlesex, UK; bThe Institute of Environment, Health
and Societies, Brunel University London, Middlesex, UK
ABSTRACT
Purpose: To describe the clinical features of electric powered indoor/outdoor wheelchair users with a
muscular dystrophy, likely to influence optimal prescription; reflecting features of muscular dystrophies,
conditions secondary to disability, and comorbidities impacting on equipment provision.
Methods: Cross-sectional retrospective case note review of recipients of electric powered indoor/outdoor
wheelchairs provided by a specialist regional wheelchair service. Data on demography, diagnostic/clinical,
and wheelchair prescription were systematically extracted.
Results: Fifty-one men and 14 women, mean age 23.7 (range 10–67, s.d. 12.95) years, were studied. Forty
had Duchenne muscular dystrophy, 22 had other forms of muscular dystrophy, and three were unclassi-
fied. Twenty-seven were aged under 19. Notable clinical features included problematic pain (10), cardio-
myopathy (5), and ventilatory failure (4). Features related to disability were (kypho)scoliosis (20) and
edema/cellulitis (3) whilst comorbidities included back pain (5). Comparison of younger with older users
revealed younger users had more features of muscular dystrophy affecting electric powered chair provi-
sion (56%) whilst older users had more comorbidity (37%). Tilt-in-space was prescribed for 81% of users,
specialized seating for 55% and complex controls for 16%.
Conclusions: Muscular dystrophy users were prescribed electric powered indoor/outdoor chairs with
many additional features reflecting the consequences of profound muscle weakness. In addition to facili-
tating independence and participation, electric powered indoor/outdoor chairs have major therapeutic
benefits.
 IMPLICATIONS FOR REHABILITATION
 Powered wheelchairs have therapeutic benefits in managing muscular dystrophy pain and weakness.
 The use of specialized seating needs careful consideration in supporting progressive muscle weakness
and the management of scoliosis.
 Pain, discomfort, pressure risk, and muscle fatigue may be reduced by use of tilt-in-space.
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Muscular dystrophy, including myotonic dystrophy, is a term cov-
ering a set of chronic, hereditary, and progressive diseases involv-
ing degeneration of muscle cells and leading to successive
wasting of the muscles including the respiratory muscles [1]. Limb
girdle muscular dystrophy is now recognized as a heterogeneous
group of myopathies that vary in severity and may affect persons
of all ages from childhood through adulthood [2]. Life expectancy
has improved markedly in recent years and Duchenne muscular
dystrophy is now considered a disease of adulthood [3].
The muscular dystrophies are rare diseases, with a “combined
prevalence between 19.8 and 25.1 per 100,000 person years” [4].
The prevalence of the commonest types are fascioscapulohumeral
dystrophy (3.2–4.6 per 100,000), myotonic dystrophy (0.5–18.1 per
100,000) and Duchenne muscular dystrophy (1.7–4.2 per 100,000)
[4]. All those with Duchenne muscular dystrophy will become
wheelchair reliant in childhood, usually by the age of 12 years
unless treated [5]. The United Kingdom (UK) Registry of fasciosca-
pulohumeral dystrophy has reported that about 40% of those reg-
istered used wheelchairs at least part-time [6]. The mean age of
achieving wheelchair reliance for those with Becker muscular dys-
trophy was 50 years [7]. Use of powered wheelchairs or powered
mobility has been reported from 7% for those with Duchenne
muscular dystrophy [8] to 31% of individuals with neuromuscular
disease [9]. The transition of both health and social support as
children transfer to adult services at the age of 19 years is recog-
nized as problematic [10,11], with inadequate adult health provi-
sion for those ageing with childhood deteriorating conditions [12].
Powered mobility is now becoming more important as its value
is increasingly accepted not only as a means of improving mobil-
ity and independence [13,14], increasing quality of life for those
with muscular dystrophies [15], potential savings in social costs
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[16]; but also because of its direct therapeutic effects [17,18].
Guidelines for those with limb girdle muscular dystrophies recom-
mend the “prescription of assistive devices that are adapted spe-
cifically for the patient’s deficiencies” [2] and guidelines for those
with Duchenne muscular dystrophy recommend assistive technol-
ogy and manual/powered wheelchairs as part of rehabilitation
management [14]. The emphasis has therefore shifted from pow-
ered wheelchairs being aids for mobility to being facilitators of
participation and occupation. Additionally, it is acknowledged that
powered wheelchairs are fundamental in optimizing medical man-
agement for those with long-term disabling conditions [18].
While powered wheelchairs are used to increase function and
mobility their provision is equally important for minimizing dis-
comfort and postural abnormalities [19]. It is acknowledged that,
as people with Duchenne muscular dystrophy grow older, they
acquire a wide range of clinical complications that need manage-
ment [20], often through specialized seating (adaptive seating) on
the powered wheelchair base. The major clinical issues relate to
orthopedic complications including fractures, (kypho)scoliosis, car-
diopulmonary involvement [20], and pain [9,21,22].
Postural problems such as a scoliosis are known to develop
when individuals are still ambulant [23]. Specialised seating can
provide appropriate postural support but this may conflict with
the desire of the chair user (hereafter described as the “user”) to
keep mobile within the chair [21]. Which may challenge a wheel-
chair provider. This challenge is compounded during the years of
growth [21] and the curve may progress even after cessation of
growth [24], associated with the increasing muscular weakness.
Regular monitoring and careful management of the spinal compli-
cations of muscular dystrophy is recommended to maintain opti-
mal posture and cardiopulmonary function [2].
The progressive muscular weakness characteristic of the muscu-
lar dystrophies determines the development of a range of clinical
manifestations which depend on the disease trajectories of the dif-
ferent types of muscular dystrophy. Many of the common features
of muscular dystrophy have been documented [2,14,25].
Individuals may also develop health conditions associated with
long-term disability. These features of disability have been
reported in other powered wheelchair users [17,26]. In addition,
individuals may be diagnosed with other conditions unrelated to
the muscular dystrophy, comorbidities, although they may reflect
age-related health issues [27]. Collectively, these have been
referred to as “Associated Clinical Features” (ACFs) [17,26] as it is
acknowledged that some ambiguity exists due to lack of research
into the development of conditions across the lifespan of disease.
The aims of this study are to describe the clinical features of
electric powered indoor/outdoor chair users with muscular dys-
trophy and to explore the complexities of comorbidities, features
of muscular dystrophy and conditions secondary to disability that
impact on powered wheelchair provision and clinical manage-
ment. A further aim is to compare the clinical features and electric
powered indoor/outdoor chair provision of those under the age
of 19 years with those aged 19 or over.
Methods
This is a cross-sectional study of a clinic population and was
approved by the National Research Ethics Service as a service
evaluation.
The participants
The potential participants for this study were wheelchair users
with a muscular dystrophy referred from locality based wheelchair
services to a specialist wheelchair service serving a mixed popula-
tion from inner city, suburban, and rural areas of 3.1 million.
Following assessment of suitability for an electric powered indoor/
outdoor chair, those who fulfilled eligibility criteria [28] were
included. Details of the specialist wheelchair service and the full
assessment for electric powered indoor/outdoor chair eligibility
have been described elsewhere [26]. In essence, those unable to
self-propel and who were able to take advantage of using a pow-
ered chair indoors and outdoors safely were included. The study
participants had been provided with an electric powered indoor/
outdoor chair and were currently using it.
Procedures
Data consisting of demographic data, clinical issues and wheel-
chair factors were entered into electronic records and reviewed
between June 2007 and September 2008 by a consultant phys-
ician in rehabilitation medicine. They were systematically extracted
and entered into a computer database. Average time from the
date of initial assessment for an electric powered indoor/outdoor
chair in clinic to the case note review was 5.28 (range 0–10.7, s.d.
3.23) years. Further data were entered from clinical notes (charts)
and anonymised.
Demographic profiles consisted of age at initial assessment
and gender. Where the database held no precise diagnostic infor-
mation relating to the type of muscular dystrophy, it was classified
as “unknown”.
Clinical profiles perceived to be relevant to the electric pow-
ered indoor/outdoor chair prescription included comorbidities,
complications relating to muscular dystrophy or disability. Due to
the ambiguity in which some clinical features may reflect either
the muscular dystrophy itself, co-morbidity or a complication of
disability, they were grouped as ACFs when referred to collectively
[17]. Users requiring further clinical management were referred to
their family doctor (primary care doctor).
Pain is a major problem for many with a muscular dystrophy
[14]. Users with pain requiring further investigation/management,
or influencing the electric powered indoor/outdoor chair prescrip-
tion were recorded as “problematic pain” [17,26].
Features noted by others as being disability related were also
included. They were spinal deformities [29,30], osteoporosis [5,31],
pelvic obliquity [29], contractures [2,5,25], thrombo-embolism [32],
dependent edema [18,33], and pressure sores [21]. Conditions
classified as comorbidities were those considered unrelated to
muscular dystrophy.
Wheelchair factors included information about specialized seat-
ing, defined as that which is “required by those who need a
wheelchair for their mobility but due to postural instability or
deformity need extra support in order to function” [34, p 0.7].
Other data included tilt-in-space, cushions, complex controls, chair
mounted ventilation and use of the National Health Service
Voucher Scheme [35].
Methods of analysis
This was a secondary data analysis of a sub-group of electric pow-
ered indoor/outdoor chair users from a cohort reported elsewhere
[36]. Descriptive statistics were used to analyze demographic, clin-
ical, and wheelchair data.
Results
Sixty-five users mean age 23.7 (range 10–67, s.d. 12.95) years
(Table 1), comprised 51men mean age 22.6 (range 10–67, s.d.
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12.9) years and 14 women mean age 27.7 (range 10–49, s.d. 12.9)
years. The dominant group of users had Duchenne muscular dys-
trophy and this group were the youngest with a mean age of
18 years (Table 1). Twenty-seven users were aged under 19 years,
the youngest aged 10, whilst 38 users were aged 19 and older,
the oldest aged 67 (Table 2).
Associated clinical features
Twenty-five users had no ACFs. Nineteen had one ACF, 14 had
two ACFs whilst seven had more than two ACFs. Of the 40 users
with Duchenne muscular dystrophy, 27 had at least one ACF.
We noted 10 comorbidities reported in 18 users, the most
common being back pain in five users. Hypertension and ischemic
heart disease were noted in users aged 54, 57, and 60. Two users,
both with congenital muscular dystrophy experienced cerebrovas-
cular events; one 33-year old had a stroke and the other aged 13
had an intracranial bleed. There were nine features of muscular
dystrophy reported by 26 users with problematic pain being the
most frequent reported by 10 users. Scoliosis was the most fre-
quently noted of the six complications of disability (n¼ 20; 10
younger and 10 older users) (Table 3). No reports were noted for
thromboembolism.
Comparison of those under 19 years with older users revealed
that the younger group had more features of muscular dystrophy
affecting electric powered indoor/outdoor chair provision (56%)
whilst the older users had more comorbidity (37%). The complica-
tions of disability were proportionately similar for younger (44%)
and older (42%) users (Table 2). Four users had ventilatory failure,
mean age 22 years, three with Duchenne muscular dystrophy and
one with congenital muscular dystrophy and required oxygen cyl-
inders to be accommodated by the electric powered indoor/out-
door chair. Two of these users had tilt-in-space and three had
specialized seating. All four were provided with tray-mounted
complex controls.
Thirty-seven users were noted to have clinical issues that needed
further attention from their family doctor (primary care team).
The majority of these referrals related to medical issues, about half
of which concerned the need for pain management.
Wheelchair features
Tilt-in-space was provided to 48 (81% of those with known data)
users (Table 1). Eighty five percent of younger users were pro-
vided with tilt-in-space, compared with 66% of older users
(Table 2). Just over half of the cohort was provided with special-
ized seating (Table 1) with 74% of younger users compared with
42% of older users having this feature (Table 2). Sixty five percent
of users with Duchenne muscular dystrophy were prescribed spe-
cialized seating compared to 40% of other muscular dystrophy
users. Thirty-one users were provided with both specialized seat-
ing and tilt-in-space although two users with specialized seating
had unknown tilt-in-space provision.
Contoured systems were provided to 12 users: carved foam (4),
Scott seating systems (4), matrix (3), and molded seat insert. The
majority of the remainder had pressure relieving cushions, mainly
Jay 2 cushion (14), Qbitus (10), Vicaire (4), RoHo (3), and Other
(n¼ 7). Fifteen were provided with a standard wheelchair cushion.
Complex controls were provided to 17 users of which 14 were
tray mounted, seven were nonstandard and six had interfacing
issues with other assistive technology devices. A further three
users were referred for environmental control units.
The voucher scheme was used by three users/parents. One 11-
year-old boy with limb girdle muscular dystrophy provided with a
“riser” function in partnership with the charity “WhizzKidz”;
another 12-year-old boy with Duchenne muscular dystrophy pro-
vided with a “lying-to-stand function” in partnership with
WhizzKidz; and a 12-year-old boy with Duchenne muscular dys-
trophy whose parents were very unhappy with the service pro-
vided and preferred the individual responsibility for maintenance
of the electric powered indoor/outdoor chair.
Table 2. Clinical features and wheelchair provision for 27 users with a muscular
dystrophy aged under 19 and 38 users aged 19 or over.
Age group Under 19 19 or more Total
No. of users 27 38 65
Mean age (range) 13.8 (10–18) 30.7 (19–67) 23.7 (10–67)
Special Seating n (%) 20 (74) 16 (42) 36 (55)
Tilt-in-Space n (%)a 23 (85) 25 (66) 48 (74)
Complex controls n (%) 6 (22) 11 (29) 17 (26)
Features of muscular dystrophy n (%) 15 (56) 11 (29) 26 (40)
Comorbidity 4 (15) 14 (37) 18 (28)
Complications of disability 12 (44) 16 (42) 28 (43)
aData unknown for six users.
Table 3. Frequency of comorbidity, features of muscular dystrophy, and compli-
cations of disability in 65 users with a muscular dystrophy.
Comorbidity Feature of MD
Complication of
disability
Back pain (5) Recurrent chest infections (2) Scoliosis (20)
Hypertension (2) Weight loss Dependent
edema/cellulitis (3)
Asthma (2) Cardiomyopathy (5) Pressure sores (2)
Cerebrovascular events (2) Problematic pain (10) Hip problems
Epilepsy (2) Ventilatory failure (4) Pelvic obliquity
Arthrogryposis Learning difficulties Contractures
Piles Swallowing difficulties
Fractures Ureteric reflux with
recurrent urinary tract
infections
Neck pain Sleep disturbance
Ischaemic heart disease
Total ¼18 Total ¼26 Total ¼28
Table 1. Age, diagnosis, and wheelchair provision for 65 users with a muscular dystrophy.
Type of muscular dystrophy No. (No. Male) Mean age (range) (years) Special Seating Tilt-in-spaceb Complex controls Scoliosis Problematic pain
Becker’s 2 (2) 42 (24–60) 0 1 0 0 0
Congenital 11 (2) 23 (11–34) 7 9 3 5 1
Duchenne 40 (40) 18 (10–34) 26 31 13 14 8
Dystrophia Myotonica 1 (1) 54a 0 1 0 0 0
Fascio-scapulo-humeral 2 (2) 45 (33–57) 0 0 0 0 0
Limb-girdle 6 (2) 36 (11–49) 2 4 1 0 1
Unknown 3 (2) 37 (10–67) 1 2 0 1 0
Total 65 (51) 23.7 (10–67) 36 48 17 20 10
aOnly one user.
bData unknown for six users.
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Discussion
Extensive follow-ups of electric powered indoor/outdoor chair
users with a muscular dystrophy are rare. This report of a UK
group spans an average of 5.3 years of electric powered indoor/
outdoor chair use by individuals with muscular dystrophy. Our
group of users are atypical when compared to other muscular
dystrophy populations. Firstly, they are all severely disabled,
unable to walk, and due to the strict eligibility criteria for electric
powered indoor/outdoor chair provision [28], those with poorly
controlled epilepsy, learning disability, and cognitive dysfunction
are under-represented. Some of these users have been reported
previously at a two-year follow-up [21].
These muscular dystrophy electric powered indoor/outdoor
chair users were on average older than most other muscular dys-
trophy populations as age was not a criterion for selection.
However, our youngest user was aged 10 years as might be
expected from the likely age of loss of walking in Duchenne mus-
cular dystrophy [37,38] and is comparable to those reported by
Engle et al. in a mixed population of users with both muscular
dystrophy and myotonic dystrophy [9]. Studies that include both
children and adults of all ages are rare, although Pangalila has
reported those with Duchenne muscular dystrophy aged up to 44
[39]. Those with Becker muscular dystrophy and fascioscapulo-
humeral dystrophy become wheelchair dependent when older as
reflected in our data and that of Wood et al. [6].
Clinical features of muscular dystrophies
The progressive muscular weakness characteristic of muscular dys-
trophies results in the decline of functional ambulation at which
point powered mobility is advocated [14]. Our study indicates that
the loss of ambulation can occur across the age range depending
on the type of muscular dystrophy. The reasons for provision of
electric powered indoor/outdoor chairs not only relate to mobility
factors, but also to the expectations of individual’s community
participation at different stages of their life [37]. The needs of
younger users, in this study mainly those with Duchenne muscular
dystrophy, include facilitating engagement in school and play
while at the same time accommodating growth and anticipated
disease progression. Older users, in this study mainly those with
other forms of muscular dystrophy, have needs relating to fami-
lies, work, and active retirement. The independence provided by
an electric powered indoor/outdoor chair facilitates psychological
and social development for younger users’ [40] and community
living for older ones [41].
In order to achieve this, electric powered indoor/outdoor chair
prescription with appropriate additional features such as special-
ized seating, should be used to reduce the impact of symptoms
and maintain or improve residual function. The findings of this
study bring together the main technical considerations of electric
powered indoor/outdoor chair provision with clinical information
relating to muscular dystrophies and severe disability.
Pain is a recognized feature of Duchenne muscular dystrophy
with higher levels reported for those still mobile as compared to
wheelchair users [42]. It is a significant problem for young people
with Duchenne muscular dystrophy affecting most parts of the
body and interfering with several life domains [9]. Engle’s patients’
reported the “pain as negatively affecting many aspects of youth
and adolescent life” [9] and also that some had severe pain which
is consistent with our findings of problematic pain. Pain was also
reported in adult patients with Duchenne muscular dystrophy but
appeared not to interfere greatly with activities [39]. Back pain,
together with leg and neck pain, are reported as common sites of
pain in neuromuscular disorders [9]. This is consistent with our
findings and indicates the need for adjustment and review of
seating [21], which in this study showed that specialized seating
was required by the majority of users, especially those under
19 years of age.
The incidence of neck pain was extremely low with only one
user reported with this problem. The likely reason was that neck
restraints were provided as standard to all our users. This is par-
ticularly important for those with progressive weakness and, in
tandem with using tilt-in-space, provides appropriate support for
the head and neck. This is an important contribution to their
rehabilitation through facilitating head control. Provision of tilt-in-
space also makes an important contribution to pain management
as it allows the user to change position as frequently as they wish
in order to minimize the pain and discomfort associated with pro-
longed sitting. Our results show a high proportion of all muscular
dystrophy electric powered indoor/outdoor chair users being pro-
vided with tilt-in-space.
Our four users with ventilatory support all had complex control
systems as has been reported previously [43]. Cardiomyopathy and
chronic respiratory insufficiency are universal in the later stages of
Duchenne muscular dystrophy [5]. It is debatable whether respira-
tory insufficiency is a consequence of muscular dystrophy progres-
sive weakness or due to chest wall and spinal deformities reducing
respiratory capacity [44]. In this cohort, specialized seating systems
were used therapeutically to facilitate reduction of spinal deformity
during growth, although after growth seating accommodated any
spinal deformity. A balance must be sought between stability and
flexibility to allow those who use a “row-a-boat” breathing to have
sufficient movement in their chairs [45].
Comorbidity
Reports of comorbidities in the muscular dystrophies are rare.
However, the “prevention and management of comorbidities” is
important [2, p 0.1461]. In common with this study, asthma has
been reported as a comorbidity in a sample of youths [9] as has
an increased risk of bone fractures in Duchenne muscular dys-
trophy [5,46]. The one user we noted with multiple fractures of
both distal femurs and proximal tibiae had tipped out of his
wheelchair, a known risk for electric powered indoor/outdoor
chair users [28]. Also, consistent with previous studies [47], we
had two users with epilepsy – one noted to be temporal lobe, the
other unspecified. This may be unrepresentative as some potential
users with epilepsy will not fulfill the eligibility criteria [28] due to
inadequate epilepsy control. We have noted epilepsy as a comor-
bidity although recent research may indicate it is part of the spec-
trum of Duchenne muscular dystrophy [48].
Comorbidities such as hypertension and ischemic heart disease
may be considered due to the ageing process, possibly related to
the sedentary lifestyle consequent to wheelchair reliance. The
cerebrovascular events noted for two electric powered indoor/out-
door chair users with congenital muscular dystrophy appear not
to have been reported previously, but it is speculated that they
may be due to cortical abnormalities noted in this condition [25].
Disability features
One of the greatest challenges for wheelchair prescribers and
those with muscular dystrophies is the development of a scoliosis
[24,49,50]. It has been reported that the magnitude of the curve
was predicted by the length of time using a wheelchair [51]. We
found 20 (31%) users with a scoliosis that required addressing
through the electric powered indoor/outdoor chair provision.
Seeking an appropriate balance between stabilizing the spine and
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retaining upper limb and trunk flexibility in the system is complex
and the views of the user and their family’s priorities may produce
tensions that need resolution by the seating team [26]. For
example, many of the users also used their manual backup chair
to extend their social life beyond the reach of their powered chair
[40]. This creates extra physical strain for the parents of these
young users when they have to transfer the seating system from
their electric powered indoor/outdoor chair to their manual chair.
Postural issues are critical in this group and are greatly compli-
cated by the influence of growth often needing adjustments to
the electric powered indoor/outdoor chair within one year of pre-
scription [21].
Dependent edema is a well-established complication of pro-
longed sitting [18] and has been noted previously in other electric
powered indoor/outdoor chair user groups [17,26] but may also be
due to electrolyte imbalance in Duchenne muscular dystrophy [52].
Pressure problems are well recognized for wheelchair depend-
ent wheelchair (not necessarily powered wheelchair) users with
Duchenne muscular dystrophy [53]. Pressure problems appear to
be better controlled now than when reported from this service
previously [21]. However, the presence of two pressure sores sug-
gests that further measures need to be taken to ensure adequate
protection against pressure.
Wheelchair issues
In contrast to other electric powered indoor/outdoor chair user
groups [17,26], these users with muscular dystrophies had a
higher frequency of provision of SS and TIS which was particularly
found for those under 19 years of age with almost half the cohort
being provided with both specialized seating and tilt-in-space. We
also found that the users with Duchenne muscular dystrophy
were most frequently provided with specialized seating. This indi-
cates both the severity of the disability, the likelihood of its pro-
gression and the complexity of meeting individuals’ needs
through the rehabilitation process.
The value of tilt-in-space has been noted previously for those
with muscular dystrophy [21,34]. It has been recommended as
good practice in the management of muscular dystrophies for
reducing the impact of gravity on a scoliosis, pressure redistribu-
tion, increasing comfort and pain relief, reducing fatigue, increas-
ing independence for the chair user to change position and
assisting carers in moving/handling in the management of per-
sonal care [34]. For this cohort of electric powered indoor/outdoor
chair users with muscular dystrophy, these issues were considered
across the age range to include chair use at home, in school, col-
lege/university, the workplace, and the outdoor environment.
Specialised seating is primarily provided to improve sitting pos-
ture, but is also reported to facilitate small improvement in upper
limb function [49], both of which are important for facilitating
function and participation. For users who are children or adoles-
cents, specialized seating may require change or adaptation to
accommodate growth [21]. Those needing the most support in
this study (12 users) were provided with individually fitted special-
ized seating. These are likely to be the most severely impaired
(e.g., through a scoliosis) and vulnerable individuals with muscular
dystrophies maintained in the community. Specialised seating was
provided for a number of other reasons, the most important
being pressure redistribution, prolongation of sitting time, pre-
venting contractures and providing the additional support needed
to negotiate ramps and slopes [33].
Trays can be used to provide additional support for the upper
limbs when arm rests prove insufficient [33]. This is particularly
important where muscle fatigue/weakness limits the residual
functions of the hands to control the electric powered indoor/out-
door chair. Provision of a tray-mounted control box alleviated this
issue for 14 of our users, six of whom utilized the tray for interfacing
with other equipment. Where the control box can be positioned
centrally, a more symmetrical posture is achieved. Complex controls,
when needed, included light touch systems appropriate for those
with extreme muscle weakness as reported previously [43].
For the four users who needed ventilatory support, the electric
powered indoor/outdoor chair prescription would have to take
into account the weight of the oxygen cylinders which are usually
mounted on the back of the chair. The engineers would allow for
the use of tilt in making their prescription. It is not surprising that
those whose cardio-respiratory weakness required ventilatory sup-
port also had such severe peripheral weakness that tray-mounted
complex controls were needed.
Health-related quality of life is severely affected by Duchenne
muscular dystrophy [54] and the consequent socioeconomic costs
of direct, indirect and informal care costs are substantial [54]. The
complexity of meeting the requirements of those with muscular
dystrophy who need powered mobility is reflected in the electric
powered indoor/outdoor chair prescription. Thus, the proportion
of those with muscular dystrophy being provided with tilt-
in-space, tilt-in-space and specialized seating, and complex controls
is greater than for those with multiple sclerosis [17], rare diseases
[26], spinal cord injuries [55], and cerebral palsy [56]. The need for
these extra features increases the capital cost of providing the elec-
tric powered indoor/outdoor chair, and also the need for extra time
from the highly skilled team of rehabilitation professionals giving
the assessment, provision, and maintenance of the chair.
Strengths and limitations
This is one of the few studies with a five-year period of follow-up
that addresses the needs of both children and adults severely
affected with a muscular dystrophy who use powered wheelchairs.
A strength of this study was that all users were seen by the same
multiprofessional team who were very experienced in the provi-
sion of powered wheelchairs and therefore the clinical decisions
made were consistent and in accordance to service protocols.
Our electric powered indoor/outdoor chair users with muscular
dystrophy were predominately those with Duchenne muscular dys-
trophy. Therefore, it is difficult to comment further on the more
specific needs of those with other types of muscular dystrophy. In
addition, we lacked precise diagnostic data regarding the type of
muscular dystrophy in three users. We acknowledge missing data
on the presence or absence of tilt-in-space in six users.
The service records did not gather data on the use of elevating
leg rests or recline features of the electric powered indoor/out-
door chair provided and this is regrettable as these features have
major therapeutic benefits, but at additional costs.
The nature of the provision of electric powered indoor/outdoor
chairs in the UK at the time of the study meant that electric pow-
ered indoor/outdoor chairs were provided to very few children
below secondary school age (10–11 years) and thus the
undoubted benefits of powered mobility for younger children
were not assessed.
We recognize that the presence of ACFs is likely to be under-
reported as data was obtained from referral letters and patient
histories. However, such data is more likely to be objective than
purely patient self-report surveys. Further prospective studies are
recommended.
This study did not include those who used scooters or had
purchased their powered wheelchairs privately or with charitable
funding (mostly available for children only).
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Conclusions
In addition to facilitating independence and participation for
those with a muscular dystrophy, powered wheelchairs have
major therapeutic benefits, particularly in the management of
wheelchair users’ pain and weakness in addition to the more rec-
ognized benefits of pressure relief.
A (kypho)scoliosis, problematic pain, and ventilatory failure
were the clinical features most likely to influence the electric pow-
ered indoor/outdoor chair prescription. Frequent use of special-
ized seating and tilt-in-space were utilized to facilitate
management of these clinical complications, whilst accommoda-
tion of the ventilatory equipment required adjustments to the
electric powered indoor/outdoor chair.
The use of powered tilt-in-space, specialized seating and com-
plex controls was greater than for any other group of electric
powered indoor/outdoor chair users studied to date and this
reflects the complexity of meeting the needs of those with pro-
found peripheral muscle weakness. This utilization was greater for
the children than for those aged 19 years or older and is likely to
reflect not only growth issues but also the rapid deterioration of
those with Duchenne muscular dystrophy and some other con-
genital forms of muscular dystrophy. The need for a high use of
these electric powered indoor/outdoor chair features will have
cost implications for neuromuscular service providers.
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